Search

Long-term follow-up after recurrent otitis media and ventilation tube insertion: Hearing outcomes and middle-ear health at six years of age

To investigate the long-term impact of recurrent otitis media (rOM) and ventilation tube insertion (VTI) in early childhood on hearing outcomes and middle-ear health three to five years later, in a prospective pregnancy cohort study.

Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing study

Serotype 24F is one of the emerging pneumococcal serotypes after the introduction of pneumococcal conjugate vaccine (PCV). We aimed to identify lineages driving the increase of serotype 24F in France and place these findings into a global context.

Cochrane CSOM: A suite of reviews examining the effectiveness of interventions to treat chronic suppurative otitis media (CSOM) globally

Chris Peter Brennan-Jones Richmond PhD MBBS MRCP(UK) FRACP Head, Ear and Hearing Health Head, Vaccine Trials Group chris.brennan-jones@thekids.org.au

Ear Explorers: A ‘real-life research project’ enabling children to view inside their own ears using smartphone video-otoscopy

Chris Brennan-Jones PhD Head, Ear and Hearing Health chris.brennan-jones@thekids.org.au Head, Ear and Hearing Health Professor Chris Brennan-Jones is

Ear Portal: An ENT and Audiology referral portal for improving access to ear health services for children using telehealth

Chris Deborah Peter Tanisha Greta Karina Brennan-Jones Lehmann Richmond Cayley Bernabei Tao PhD AO, MBBS, MSc MBBS MRCP(UK) FRACP BBiomed (Hons) BSc

Koorlungkas yarning: Exploring the impact of OM on early language and communication skills in urban Aboriginal families

Deborah Peter Lehmann Richmond AO, MBBS, MSc MBBS MRCP(UK) FRACP Honorary Emeritus Fellow Head, Vaccine Trials Group Honorary Emeritus Fellow Head,

Clinical Associate Professor Deborah Lehmann

Honorary Emeritus Fellow

Project helps Ethan belong

Ethan recently took part in Belong, a study led by The Kids which aims to ensure deaf and hard of hearing kids have a happy & positive school experience

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.

“You’re telling us to go first?!” COVID-19 pandemic and vaccination experiences among Aboriginal adults in Western Australia

Globally, Indigenous populations have been disproportionately impacted by pandemics. In Australia, though national infection rates with COVID-19 infections in Aboriginal and/or Torres Strait Islander people were lower in the first 12 months of the COVID-19 pandemic, there was soon a greater burden in Aboriginal and/or Torres Strait Island people once Omicron was circulating. Uptake of the COVID-19 vaccine was also lower among Aboriginal and/or Torres Strait Islander people.